Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.

Kreijne JE, de Veer RC, de Boer NK, Dijkstra G, West R, Moorsel SAW, de Jong DJ, van der Woude CJ, de Vries AC; of the Dutch Initiative on Crohn, Colitis (ICC).

Aliment Pharmacol Ther. 2019 Aug;50(4):407-415. doi: 10.1111/apt.15402.

PMID:
31359480
2.

Recent trend reversal for declining European seagrass meadows.

de Los Santos CB, Krause-Jensen D, Alcoverro T, Marbà N, Duarte CM, van Katwijk MM, Pérez M, Romero J, Sánchez-Lizaso JL, Roca G, Jankowska E, Pérez-Lloréns JL, Fournier J, Montefalcone M, Pergent G, Ruiz JM, Cabaço S, Cook K, Wilkes RJ, Moy FE, Trayter GM, Arañó XS, de Jong DJ, Fernández-Torquemada Y, Auby I, Vergara JJ, Santos R.

Nat Commun. 2019 Jul 26;10(1):3356. doi: 10.1038/s41467-019-11340-4.

3.

Living in the intertidal: desiccation and shading reduce seagrass growth, but high salinity or population of origin have no additional effect.

Suykerbuyk W, Govers LL, van Oven WG, Giesen K, Giesen WBJT, de Jong DJ, Bouma TJ, van Katwijk MM.

PeerJ. 2018 Jul 20;6:e5234. doi: 10.7717/peerj.5234. eCollection 2018.

4.

Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.

Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F.

Inflamm Bowel Dis. 2019 Jan 1;25(1):172-179. doi: 10.1093/ibd/izy227.

PMID:
29947795
5.

Addition of simethicone improves small bowel capsule endoscopy visualisation quality.

Krijbolder MS, Grooteman KV, Bogers SK, de Jong DJ.

Neth J Med. 2018 Jan;76(1):27-31.

6.

Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease.

Visschedijk MC, Spekhorst LM, Cheng SC, van Loo ES, Jansen BHD, Blokzijl T, Kil H, de Jong DJ, Pierik M, Maljaars JPWJ, van der Woude CJ, van Bodegraven AA, Oldenburg B, Löwenberg M, Nieuwenhuijs VB, Imhann F, van Sommeren S, Alberts R, Xavier RJ, Dijkstra G, Nico Faber K, Aldaz CM, Weersma RK, Festen EAM.

J Crohns Colitis. 2018 Apr 27;12(5):582-588. doi: 10.1093/ecco-jcc/jjy001.

PMID:
29361163
7.

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease.

Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D'Haens G, Löwenberg M, Weersma RK, Festen EAM; Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis.

World J Gastroenterol. 2017 Dec 14;23(46):8182-8192. doi: 10.3748/wjg.v23.i46.8182.

8.

Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.

Broekman MMTJ, Wanten GJ, de Jong DJ.

Aliment Pharmacol Ther. 2018 Jan;47(1):130-131. doi: 10.1111/apt.14395. No abstract available.

9.

The NOD2 receptor is crucial for immune responses towards New World Leishmania species.

Dos Santos JC, Damen MSMA, Oosting M, de Jong DJ, Heinhuis B, Gomes RS, Araújo CS, Netea MG, Ribeiro-Dias F, Joosten LAB.

Sci Rep. 2017 Nov 9;7(1):15219. doi: 10.1038/s41598-017-15412-7.

10.

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease.

Spekhorst LM, Imhann F, Festen EAM, van Bodegraven AA, de Boer NKH, Bouma G, Fidder HH, d'Haens G, Hoentjen F, Hommes DW, de Jong DJ, Löwenberg M, Maljaars PWJ, van der Meulen-de Jong AE, Oldenburg B, Pierik MJ, Ponsioen CY, Stokkers PC, Verspaget HW, Visschedijk MC, van der Woude CJ, Dijkstra G, Weersma RK; Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC).

BMJ Open. 2017 Nov 8;7(11):e016695. doi: 10.1136/bmjopen-2017-016695.

11.

Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Kievit W, Klungel OH, Verbeek ALM, Wong DR, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Bouvy ML, de Jong DJ.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):167-173. doi: 10.1097/MEG.0000000000001025.

12.

The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study.

Spekhorst LM, Severs M, de Boer NKH, Festen EAM, Fidder HH, Hoentjen F, Imhann F, de Jong DJ, van der Meulen-de Jong AE, Pierik MJ, van der Woude CJ, Dijkstra G, Ponsioen CY, Löwenberg M, Oldenburg B, Weersma RK; Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis.

J Crohns Colitis. 2017 Dec 4;11(12):1463-1470. doi: 10.1093/ecco-jcc/jjx098.

PMID:
28981621
13.

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Wong DR, de Jong DJ.

Aliment Pharmacol Ther. 2017 Nov;46(10):953-963. doi: 10.1111/apt.14323. Epub 2017 Sep 15.

14.

Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.

Severs M, Mangen MJ, Fidder HH, van der Valk ME, van der Have M, van Bodegraven AA, Clemens CHM, Dijkstra G, Jansen JM, de Jong DJ, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Romberg-Camps MJL, Siersema PD, Jharap B, van der Woude JC, Zuithoff NPA, Oldenburg B.

Inflamm Bowel Dis. 2017 Sep;23(9):1568-1576. doi: 10.1097/MIB.0000000000001201.

PMID:
28700534
15.

Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.

Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.

Dig Dis Sci. 2017 Nov;62(11):3117-3122. doi: 10.1007/s10620-017-4661-4. Epub 2017 Jun 30.

16.

More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.

Broekman MMTJ, Coenen MJH, van Marrewijk CJ, Wanten GJA, Wong DR, Verbeek ALM, Klungel OH, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, de Jong DJ; TOPIC Recruitment Team.

Inflamm Bowel Dis. 2017 Oct;23(10):1873-1881. doi: 10.1097/MIB.0000000000001163.

17.

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.

Broekman MMTJ, Wong DR, Wanten GJA, Roelofs HM, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Coenen MJH, de Jong DJ.

Pharmacogenomics J. 2018 Jan;18(1):160-166. doi: 10.1038/tpj.2016.87. Epub 2017 Jan 3.

PMID:
28045129
18.

Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease.

Nissen LH, Assendorp EL, van der Post RS, Derikx LA, de Jong DJ, Kievit W, Pierik M, van den Heuvel T, Verhoeven R, Overbeek LI, Hoentjen F, Nagtegaal ID.

J Gastrointestin Liver Dis. 2016 Dec;25(4):431-440. doi: 10.15403/jgld.2014.1121.254.nis.

19.

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.

Wong DR, Coenen MJ, Derijks LJ, Vermeulen SH, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC Recruitment Team.

Aliment Pharmacol Ther. 2017 Feb;45(3):391-402. doi: 10.1111/apt.13879. Epub 2016 Dec 12.

20.

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.

Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F.

J Crohns Colitis. 2016 Nov;10(11):1287-1293. Epub 2016 Apr 19.

PMID:
27095751
21.

Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.

Severs M, Mangen MJ, van der Valk ME, Fidder HH, Dijkstra G, van der Have M, van Bodegraven AA, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, Ponsioen CY, Vermeijden JR, van der Meulen-de Jong AE, Pierik M, Siersema PD, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis.

J Crohns Colitis. 2017 Mar 1;11(3):342-352. doi: 10.1093/ecco-jcc/jjw160.

PMID:
27647859
22.

Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2.

Visschedijk MC, Alberts R, Mucha S, Deelen P, de Jong DJ, Pierik M, Spekhorst LM, Imhann F, van der Meulen-de Jong AE, van der Woude CJ, van Bodegraven AA, Oldenburg B, Löwenberg M, Dijkstra G, Ellinghaus D, Schreiber S, Wijmenga C; Initiative on Crohn and Colitis; Parelsnoer Institute, Rivas MA, Franke A, van Diemen CC, Weersma RK.

PLoS One. 2016 Aug 4;11(8):e0159609. doi: 10.1371/journal.pone.0159609. eCollection 2016.

23.

The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.

van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.

Inflamm Bowel Dis. 2016 Sep;22(9):2112-20. doi: 10.1097/MIB.0000000000000869.

PMID:
27482972
24.

Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.

Wong DR, Coenen MJ, Vermeulen SH, Derijks LJ, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC recruitment team.

J Crohns Colitis. 2017 Feb;11(2):175-184. doi: 10.1093/ecco-jcc/jjw130. Epub 2016 Jul 9.

PMID:
27402913
25.

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.

van der Valk ME, Mangen MJ, Severs M, van der Have M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk C, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis.

PLoS One. 2016 Apr 21;11(4):e0142481. doi: 10.1371/journal.pone.0142481. eCollection 2016.

26.

Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.

Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, van Bodegraven AA, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, Ponsioen CY, Bolwerk C, Vermeijden JR, Pierik MJ, Siersema PD, Leenders M, van der Meulen-de Jong AE, Dijkstra G, Oldenburg B; Dutch Initiative on Crohn and Colitis.

J Crohns Colitis. 2016 Apr;10(4):455-61. doi: 10.1093/ecco-jcc/jjv238. Epub 2015 Dec 30.

27.

Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy.

van der Valk ME, Mangen MJ, Severs M, van der Have M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk C, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B; COIN study group; Dutch Initiative on Crohn and Colitis.

J Crohns Colitis. 2015 Nov;9(11):1016-23. doi: 10.1093/ecco-jcc/jjv134. Epub 2015 Aug 7.

PMID:
26254056
28.

LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease.

Broekman MM, Roelofs HM, Hoentjen F, Wiegertjes R, Stoel N, Joosten LA, de Jong DJ, Wanten GJ.

PLoS One. 2015 Jul 24;10(7):e0133932. doi: 10.1371/journal.pone.0133932. eCollection 2015.

29.

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team.

Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11.

PMID:
26072396
30.

Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro.

Broekman MM, Roelofs HM, Wong DR, Kerstholt M, Leijten A, Hoentjen F, Peters WH, Wanten GJ, de Jong DJ.

Cell Biol Toxicol. 2015 Jun;31(3):161-71. doi: 10.1007/s10565-015-9301-1. Epub 2015 Apr 28.

31.

Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders.

Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, van Krieken JH, Hoentjen F.

J Crohns Colitis. 2015 May;9(5):398-403. doi: 10.1093/ecco-jcc/jjv040. Epub 2015 Mar 4.

PMID:
25740811
32.

Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions.

van der Have M, Fidder HH, Leenders M, Kaptein AA, van der Valk ME, van Bodegraven AA, Dijkstra G, de Jong DJ, Pierik M, Ponsioen CY, van der Meulen-de Jong AE, van der Woude CJ, van de Meeberg PC, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, Bolwerk CJ, Vermeijden JR, Siersema PD, Oldenburg B; COIN study group; Dutch Initiative on Crohn and Colitis.

Inflamm Bowel Dis. 2015 Feb;21(2):369-77. doi: 10.1097/MIB.0000000000000278.

PMID:
25569738
33.

Recognition of Coxiella burnetii by toll-like receptors and nucleotide-binding oligomerization domain-like receptors.

Ammerdorffer A, Schoffelen T, Gresnigt MS, Oosting M, den Brok MH, Abdollahi-Roodsaz S, Kanneganti TD, de Jong DJ, van Deuren M, Roest HJ, Rebel JM, Netea MG, Joosten LA, Sprong T.

J Infect Dis. 2015 Mar 15;211(6):978-87. doi: 10.1093/infdis/jiu526. Epub 2014 Sep 22.

PMID:
25246533
34.

GST Theta null genotype is associated with an increased risk for ulcerative colitis: a case-control study and meta-analysis of GST Mu and GST Theta polymorphisms in inflammatory bowel disease.

Broekman MM, Bos C, Te Morsche RH, Hoentjen F, Roelofs HM, Peters WH, Wanten GJ, de Jong DJ.

J Hum Genet. 2014 Oct;59(10):575-80. doi: 10.1038/jhg.2014.77. Epub 2014 Sep 4.

PMID:
25186055
35.

Recognition of Streptococcus pneumoniae and muramyl dipeptide by NOD2 results in potent induction of MMP-9, which can be controlled by lipopolysaccharide stimulation.

Vissers M, Hartman Y, Groh L, de Jong DJ, de Jonge MI, Ferwerda G.

Infect Immun. 2014 Dec;82(12):4952-8. doi: 10.1128/IAI.02150-14. Epub 2014 Sep 2.

36.

Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: a study in Crohn's disease.

Prager M, Durmus T, Büttner J, Molnar T, de Jong DJ, Drenth JP, Baumgart DC, Sturm A, Farkas K, Witt H, Büning C.

Scand J Gastroenterol. 2014 Oct;49(10):1191-200. doi: 10.3109/00365521.2014.928903. Epub 2014 Aug 6.

PMID:
25098938
37.

Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future.

van der Have M, Mangen MJ, van der Valk ME, Smeets HM, van Bodegraven A, Dijkstra G, Fidder HH, de Jong DJ, Pierik M, Ponsioen CY, van der Meulen-de Jong AE, van der Woude CJ, van de Meeberg PC, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, Bolwerk CJ, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B; COIN Study Group; Dutch Initiative on Crohn and Colitis.

Inflamm Bowel Dis. 2014 Apr;20(4):637-45. doi: 10.1097/01.MIB.0000442677.55051.03.

PMID:
24518606
38.

Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease.

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; COIN study group; Dutch Initiative on Crohn and Colitis.

J Crohns Colitis. 2014 Jul;8(7):590-7. doi: 10.1016/j.crohns.2013.11.019. Epub 2013 Dec 16.

PMID:
24351733
39.

Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease.

Derikx LA, Kievit W, Drenth JP, de Jong DJ, Ponsioen CY, Oldenburg B, van der Meulen-de Jong AE, Dijkstra G, Grubben MJ, van Laarhoven CJ, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis.

Gastroenterology. 2014 Jan;146(1):119-28.e1. doi: 10.1053/j.gastro.2013.09.047. Epub 2013 Sep 25.

PMID:
24076060
40.

Elective switching from infliximab to adalimumab in stable Crohn's disease.

Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):761-6. doi: 10.1097/MIB.0b013e3182802ae1.

PMID:
23446337
41.

Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.

Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA; Dutch Initiative on Crohn and Colitis.

Gut. 2014 Mar;63(3):451-7. doi: 10.1136/gutjnl-2012-303615. Epub 2013 Feb 19.

PMID:
23424097
42.

Evaluation of long-term function, complications, quality of life and health status after restorative proctocolectomy with ileo neo rectal and with ileal pouch anal anastomosis for ulcerative colitis.

Heikens JT, de Vries J, de Jong DJ, den Oudsten BL, Hopman W, Groenewoud JM, van der Kolk MB, Gooszen HG, van Laarhoven CJ.

Colorectal Dis. 2013 Jun;15(6):e323-9. doi: 10.1111/codi.12175.

PMID:
23406347
43.

Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia.

van Schaik FD, Mooiweer E, van der Have M, Belderbos TD, Ten Kate FJ, Offerhaus GJ, Schipper ME, Dijkstra G, Pierik M, Stokkers PC, Ponsioen C, de Jong DJ, Hommes DW, van Bodegraven AA, Siersema PD, van Oijen MG, Oldenburg B; Dutch Initiative on Crohn Colitis.

Inflamm Bowel Dis. 2013 Feb;19(2):342-9. doi: 10.1097/MIB.0b013e318286f771.

PMID:
23340679
44.

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis.

Gut. 2014 Jan;63(1):72-9. doi: 10.1136/gutjnl-2012-303376. Epub 2012 Nov 7.

PMID:
23135759
45.

Suppressing antagonistic bioengineering feedbacks doubles restoration success.

Suykerbuyk W, Bouma TJ, van der Heide T, Faust C, Govers LL, Giesen WB, de Jong DJ, van Katwijk MM.

Ecol Appl. 2012 Jun;22(4):1224-31.

PMID:
22827130
46.

Respiratory syncytial virus infection augments NOD2 signaling in an IFN-β-dependent manner in human primary cells.

Vissers M, Remijn T, Oosting M, de Jong DJ, Diavatopoulos DA, Hermans PW, Ferwerda G.

Eur J Immunol. 2012 Oct;42(10):2727-35. doi: 10.1002/eji.201242396. Epub 2012 Aug 20.

47.

Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.

de Vries HS, de Heij T, Roelofs HM, te Morsche RH, Peters WH, de Jong DJ.

Dig Dis Sci. 2012 Jun;57(6):1604-8. doi: 10.1007/s10620-012-2159-7. Epub 2012 Apr 26.

48.

High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials.

Römkens TE, Kampschreur MT, Drenth JP, van Oijen MG, de Jong DJ.

Inflamm Bowel Dis. 2012 Nov;18(11):2190-8. doi: 10.1002/ibd.22939. Epub 2012 Mar 14. Review.

PMID:
22419617
49.

A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease.

de Vries HS, Te Morsche RH, Jenniskens K, Peters WH, de Jong DJ.

J Crohns Colitis. 2012 Jun;6(5):597-602. doi: 10.1016/j.crohns.2011.11.010. Epub 2011 Dec 16.

PMID:
22398043
50.

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.

Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, Weersma RK, van der Woude CJ, Stapelbroek JM, Schipper ME, Wijmenga C, van Erpecum KJ, Oldenburg B; Dutch Initiative on Crohn, Colitis (ICC).

PLoS One. 2011;6(8):e23745. doi: 10.1371/journal.pone.0023745. Epub 2011 Aug 22.

Supplemental Content

Loading ...
Support Center